Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects who have completed studies 998HB102 (NCT01027364) or 9HB02PED (NCT01440946) or other studies with rFIXFc~* Ability to understand the purposes \& risks of the study and provide signed and dated informed consent.~Key Exclusion Criteria:~* High-titer inhibitor (\>/=5.00 BU/mL)~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On-Demand (Type: EXPERIMENTAL): The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
- Prophylaxis (Type: EXPERIMENTAL): Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.

Based on this trial design, predict the completion outcome and termination type (if applicable).